Harness the power of deep proteomic screening to access undruggable targets

NEOsphere Biotechnologies offers unique proteomics expertise to discover novel targets of small molecule degraders. Located in Munich’s biotech hub, we leverage latest mass spectrometry technologies to screen libraries of tens of thousands of compounds against proteomes of more than 10,000 proteins. Our purpose-built data analysis platform systematically extracts neo-substrate candidates, which we validate as new degrader targets by approaches such as ubiquitination analysis to an unparalleled depth of 50,000 sites.

NEOsphere’s integrated target discovery engine is driving value generation by connecting innovative degrader chemistries with the previously undruggable proteome. This creates numerous new avenues for drug discovery, to build broad and robust pipelines of first-in-class therapeutics modulating novel, high-value targets.

Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.